Search Orphan Drug Designations and Approvals
-
Generic Name: | encorafenib |
---|---|
Date Designated: | 11/19/2013 |
Orphan Designation: | Treatment of Stage IIB-IV melanoma positive for BRAF mutation |
Orphan Designation Status: | Designated/Designation Withdrawn or Revoked |
Date Designation Withdrawn or Revoked: | 07/06/2022 |
FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
Sponsor: |
Array BioPharma Inc., a wholly-owned subsidiary of Pfizer Inc. 125 Cambridge Park Drive Suite 301 Cambridge, Massachusetts 02140 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-